Experienced in Pleural Effusion

Xingxiang B. Xu

28 Nan Tong Road, 
Yangzhou, CN 
Experienced in Pleural Effusion
28 Nan Tong Road, 
Yangzhou, CN 
OverviewLocationsClinical Research

Overview

Xingxiang Xu practices in Yangzhou, China. Xu is rated as an Experienced expert by MediFind in the treatment of Pleural Effusion. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Metastatic Pleural Tumor, and Small Cell Lung Cancer (SCLC).

Their clinical research consists of co-authoring 39 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Pleural Effusion.

Locations

28 Nan Tong Road, Yangzhou, 225001, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Unknown
Publish Date: March 08, 2023
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
A Phase 2 Study to Evaluate the Safety and Efficacy of Human Monoclonal Antibodies, BRII-196 and BRII-198, Administered by Intravenous Infusion for the Treatment of COVID-19 Patients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

39 Total Publications

Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer.
Comprehensive first-in-human phase I/II study of FHND-9041 in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Xu's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile